Rechazo subclínico, una entidad de interés emergente

Nefrologia

Volumn 26, Issue SUPPL.7, 2006, Pages 3-14

  Seron D ^a   O'Valle, F ^b   Moreso, F ^a   Garcia del Moral R ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PATHOLOGY; REVIEW; RISK FACTOR;

CHRONIC DISEASE; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 38449098714     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Racusen LC, Solez K, Colvin RB y cols.: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999.
2. Ratner MI, Tomilina NA, Alekseev LP, Fedorova ND: Subclinical crises of kidney allotransplantation rejection. Vestn Akad Med Nauk SSSR 28: 59-64, 1973.
3. Matas AJ, Sibley R, Mauer SM y cols.: Pre-discharge, posttransplant kidney biopsies does not predict rejection. J Surg Res 32: 269-274, 1982.
4. Burdick JF, Beschorner WE, Smith WJ y cols.: Characteristics of early routine renal allograft biopsies. Transplantation 38: 679-683, 1984.
5. Isoniemi H, Krogerus L, Von Willebrand E, Taskinen E, Ahonen J, Häyry P: Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 41: 155-160, 1992.
6. Marcusen N, Olsen TS, Benediktsson H y cols.: Reproducibility of the Banff classification of renal allograft pathology. Transplantation 60: 1083-1089, 1995.
7. Furness PN, Taub N: International variation in the interpretation of renal transplant biopsies: report of the CERTPAP project. Kidney Int 60: 1198-2010, 2001.
8. Colvin RB, Cohen AH, Saiontz C y cols.: Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 8: 1930-1941, 1997.
9. Veronese FV, Manfro RC, Roman FR y cols.: Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 19: 518-521, 2005.
10. Rush DN, Jeffery JR, Gough J: Sequential protocol biopsies in renal transplant patients. Transplantation 59: 511-514, 1995.
11. Serón D, Moreso F, Bover J y cols.: Early protocol renal allograft biopsies and graft outcome. Kidney Int 51: 310-316, 1997.
12. Legendre C, Thervet E, Skiri H y cols.: Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 65: 1506-1509, 1998.
13. Serón D, Moreso F, Ramón JM y cols.: Protocol renal allografts biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 69: 1849-1855, 2000.
14. Nankivell BJ, Fenton-Lee CA, Kuypers DR y cols.: Effect of histological damage on long-term kidney outcome. Transplantation 71: 515-521, 2001.
15. Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM: Reliabiltiy of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 61: 727-733, 2002.
16. Roberts ISD, Reddy S, Russell C y cols.: Subclinical rejection and borderline changes in early protocol biopsies specimens after renal transplantation. Transplantation 77: 1194-1198, 2004.
17. Choi BS, Shin MJ, Sjin SJ y cols.: Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 5: 1354-1360, 2005.
18. Mengel M, Bogers J, Bosmans JL y cols.: Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 5: 193-201, 2005.
19. Ishikawa MM, Mizuiri S, Aikawa A, Ohara T, Hasegawa A: Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant 19: 456-465, 2005.
20. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RDM, Chapman JR: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 78: 242-249, 2004.
21. Moreso F, Ibernon M, Goma M y cols.: Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 6: 747-752, 2006.
22. Moreso F, Seron D, Gil-Vernet S y cols.: Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Nephrol Dial Transplant 14: 930-935, 1999.
23. 1 levels. Transplantation 1: 1463-1466, 2006.
24. Tinckam K, Rush D, Hutchinson I y cols.: The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology. Transplantation 79: 836-841, 2005.
25. Mytilineos J, Laux G, Opelz G.: Relevance of IL10, TGFâ1, TNFá and IL4Rá gene polymorphisms in kidney transplantation: a collaborative study report. Am J Transplant 4: 1684-1671, 2004.
26. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PO, Allen RDM, Chapman JR: The natural history of chronic allograft nephropathy. N Eng J Med 349: 2326-2333, 2003.
27. Ibernon M, Goma M, Moreso F y cols.: Subclinical rejection impairs glomerular adaptation after renal transplantation. Kidney Int 2006 (en prensa).
28. Bonsib SM, Abul-Ezz SR, Ahmad I y cols.: Acute rejection-associated tubular basement membrane defects and chronic allograft nephropathy. Kidney Int 58: 2206-2014, 2000.
29. Rush DN, Nickerson P, Gough J y cols.: Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 9: 2129-2134, 1998.
30. Miyagi M, Ishikawa Y, Mizuiri S, Aikawa A, Ohara T, Hasegawa A: Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant 19: 456-465, 2005.
31. Moreso F, Seron D, Carrera M y cols.: Baseline inmunosuppresion is associated with histological findings in early protocol biopsies. Transplantation 78: 1064-1068, 2004.
32. Gloor JM, Cohen AJ, Lager DJ y cols.: Subclinical rejection in tacrolimus-treated renal transplant patients. Transplantation 1965-1968, 2002.
33. Nickerson P, Jeffery J, Gough J y cols.: Effect of increasing baseline immunosuppression on the prevalence of subclinical rejection: a pilot study. J Am Soc Nephrol 10: 1801-1805, 1999.
34. Barama A, Sepandj F, Gough J, McKenna R: Correlation between Neoral 2 hours post-dose and histologic findings on surveillance biopsies. Transplant Proc 36 (Supl. 2): 465S-467S, 2004.
35. Anil Kumar MS, Heifets M, Fyfe B y cols.: Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/ sirolimus combination in kidney transplantation monitored by surveillance biopsies. Transplantation 80: 807-814, 2005.
36. Mota A, Arias M, Taskinen EI y cols.: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4: 953-961, 2004.
37. Buehrig CK, Lager DJ, Stegall MD y cols.: Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 64: 665-673, 2003.
38. Shishido S, Asanuma H, Nakai H y cols.: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14: 1046-1052, 2003.
39. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD: Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5: 2464-2472, 2005.
40. Grimm PC, McKenna R, Nickerson P y cols.: Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 10: 1582-1589, 1999.
41. Lipman M, Shen Y, Jeffery J y cols.: Immune activation gene expression in stable renal allograft biopsies: molecular evidence for subclinical rejection. Transplantation 66: 1673-1681, 1998.
42. Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE, Ten Berge IJM: Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int 66: 1417-1422, 2004.
43. Veronese FV, Noronha IL, Manfro RC, Edelweiss MI, Goldberg J, Gonçalves LF: Prevalence and immunohistochemichal findings of subclinical kidney allograft rejection and its association with graft outcome. Clin Transplant 18: 357-364, 2004.
44. Sarwal M, Chua MS, Kambham N y cols.: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Eng J Med 349: 125-138, 2003.
45. Li B, Hartono C, Ding R y cols.: Non invasive diagnosis of renal allograft rejection by measurement of messenger RNA for perforine and granzyme B in urine. N Eng J Med 344: 947-954, 2001.
46. Muthukumar T, Dadhania D, Ding R y cols.: Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Eng J Med 353: 2342-2351, 2005.
47. Schaub S, Rush D, Wilkins J y cols.: Proteomic-based detection of urine proteins associated with renal allograft rejection. J Am Soc Nephrol 15: 219-227, 2004.
48. Wittke S, Haubitz M, Walden M y cols.: Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant rejection. Am J Transplant 5: 2479-2488.